Charles Schwab
KRTX

Charles Schwab’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Charles Schwab’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-225,060
Closed -$71.2M – 3542
2023
Q4 		$71.2M Buy
225,060
+6,721
+3% +$1.31M 0.02% 738
2023
Q3 		$36.9M Buy
218,339
+32,548
+18% +$6.12M 0.01% 1100
2023
Q2 		$40.3M Sell
185,791
-65,297
-26% -$14M 0.01% 1007
2023
Q1 		$45.6M Buy
251,088
+20,021
+9% +$3.83M 0.01% 904
2022
Q4 		$45.4M Buy
231,067
+13,552
+6% +$2.91M 0.01% 886
2022
Q3 		$48.9M Buy
217,515
+46,168
+27% +$9.34M 0.02% 773
2022
Q2 		$21.7M Buy
171,347
+10,956
+7% +$1.26M 0.01% 1349
2022
Q1 		$20.3M Buy
160,391
+4,332
+3% +$488K 0.01% 1538
2021
Q4 		$20.4M Buy
156,059
+3,186
+2% +$412K 0.01% 1558
2021
Q3 		$18.7M Buy
152,873
+15,657
+11% +$1.81M 0.01% 1646
2021
Q2 		$15.6M Buy
137,216
+16,359
+14% +$1.91M 0.01% 1751
2021
Q1 		$14.5M Buy
120,857
+13,685
+13% +$1.55M 0.01% 1743
2020
Q4 		$10.9M Buy
107,172
+1,719
+2% +$159K ﹤0.01% 1819
2020
Q3 		$8.15M Buy
105,453
+25,090
+31% +$2.14M ﹤0.01% 1823
2020
Q2 		$8.96M Buy
80,363
+14,957
+23% +$1.3M ﹤0.01% 1717
2020
Q1 		$4.71M Buy
65,406
+21,822
+50% +$1.87M ﹤0.01% 1868
2019
Q4 		$3.28M Buy
43,584
+11,329
+35% +$496K ﹤0.01% 2232
2019
Q3 		$527K Buy
+32,255
New +$627K ﹤0.01% 2781

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Charles Schwab's KRTX Position: Q1 2024 in Review

Charles Schwab sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 225,060 shares — an estimated $71.2M sold.

Charles Schwab first reported a position in KRTX in Q3 2019 and held it in 18 quarters. The position peaked at $71.2M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Charles Schwab reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Charles Schwab sold 225,060 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $71.2M.
  • Charles Schwab first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2019 and held it in 18 quarters.
  • Charles Schwab's Karuna Therapeutics, Inc. Common Stock position peaked at $71.2M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.